IN-VIVO TIME AND DOSE-DEPENDENCY OF INTERLEUKIN-6 SECRETION IN RESPONSE TO LOW-DOSE SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2

被引：13

作者：

MEFFERT, M ^{[1
]}

HANNINEN, EL ^{[1
]}

MENZEL, T ^{[1
]}

SCHOMBURG, A ^{[1
]}

DUENSING, S ^{[1
]}

DALLMANN, I ^{[1
]}

GROSSE, J ^{[1
]}

VOCKE, S ^{[1
]}

BUER, J ^{[1
]}

DECKERT, M ^{[1
]}

HILSE, R ^{[1
]}

KIRCHNER, H ^{[1
]}

POLIWODA, H ^{[1
]}

ATZPODIEN, J ^{[1
]}

机构：

[1] HANNOVER MED SCH,HAMATOL & ONKOL ABT 6860,D-30623 HANNOVER,GERMANY

来源：

CANCER BIOTHERAPY | 1994年 / 9卷 / 04期

关键词：

INTERLEUKIN-2; INTERLEUKIN-6; RENAL CELL CARCINOMA;

D O I：

10.1089/cbr.1994.9.307

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Serum concentrations of Interleukin-6 (IL-6) were determined in renal cell carcinoma patients treated with low-dose subcutaneous human recombinant interleukin-2 (rIL-2). In all patients, administration of rIL-2 resulted in a significant increase in IL-6 serum levels to peak values within 4 to 6 hours as measured by enzyme-linked immunosorbent assays (ELISA). Repetitive administration of rIL-2 induced significantly lower IL-6 serum peaks when compared to the initial administration of rIL-2. Cumulative IL-6 release, as expressed by the area under the concentration curve (AUC), appeared to be independent of rIL-2 dose distribution (10 million IU rIL-2/m2 versus 20 million IU rIL-2/m2), and IL-6 serum peaks showed no direct dose dependency. Prior rIL-2 immunotherapy had no measurable effect on rIL-2 induced IL-6 release, while steroids resulted in a significant suppression of secondary IL-6. Release of IL-6 did not correlate with response to rIL-2 therapy or survival of rIL-2 treated renal cell carcinoma patients.

引用

页码：307 / 316

页数：10

共 42 条

[1] HOME THERAPY WITH RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA-2B IN ADVANCED HUMAN MALIGNANCIES
ATZPODIEN, J
KORFER, A
FRANKS, CR
POLIWODA, H
KIRCHNER, H
[J]. LANCET, 1990, 335 (8704) : 1509 - 1512
[2] SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS
BATAILLE, R
JOURDAN, M
ZHANG, XG
KLEIN, B
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) : 2008 - 2011
[3] BEUTLER B, 1986, SCIENCE, P977
[4] BLAY JY, 1990, CANCER RES, V50, P2371
[5] BLAY JY, 1992, CANCER RES, P3317
[6] INTERLEUKINS - CLINICAL PHARMACOKINETICS AND PRACTICAL IMPLICATIONS
BOCCI, V
[J]. CLINICAL PHARMACOKINETICS, 1991, 21 (04) : 274 - 284
[7] BROUCKAERT P, 1985, J EXP MED, V169, P2257
[8] ETTINGHAUSEN SE, 1987, BLOOD, V69, P1654
[9] B-CELL-STIMULATORY FACTOR-II (BETA-2 INTERFERON) FUNCTIONS AS A 2ND SIGNAL FOR INTERLEUKIN-2 PRODUCTION BY MATURE MURINE T-CELLS
GARMAN, RD
JACOBS, KA
CLARK, SC
RAULET, DH
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) : 7629 - 7633
[10] INTERFERON BETA-2/B-CELL STIMULATORY FACTOR TYPE-2 SHARES IDENTITY WITH MONOCYTE-DERIVED HEPATOCYTE-STIMULATING FACTOR AND REGULATES THE MAJOR ACUTE PHASE PROTEIN RESPONSE IN LIVER-CELLS
GAULDIE, J
RICHARDS, C
HARNISH, D
LANSDORP, P
BAUMANN, H
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (20) : 7251 - 7255

← 1 2 3 4 5 →